Abbott Spins Off its Hospital Products Group--and Then There Were None

Abbott's announced spin-off of its hospital supply business suggests once and for all that a key medical device model of the 1980s is now dead. At the same time, it creates an enormous company with significant resources.

Twenty years ago, the medical device industry was largely a hospital supply business and that hospital supply business was dominated by a pantheon of large companies—American Hospital Supply Corp., Johnson & Johnson , and Abbott Laboratories Inc. —all of whom sold a broad array of hospital-based products through advanced marketing and distribution networks. Other suppliers, including Becton, Dickinson & Co., CR Bard Inc. , Kendall, and Sherwood Medical, the last two now part of Tyco International Ltd. , endorsed the model, if they didn't copy it outright, by making distribution and channel management a critical priority. More importantly, virtually all saw a broad-based approach to hospital supply as crucial.

The announcement that Abbott is spinning off its hospital products group (HPG) represents the final bell tolling for such a...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.